Key result
The 11beta-HSD1 inhibitor 2922 improves glucose homeostasis but fails to alter atherosclerosis in mice.
Answers are grounded in this paper and cite their sources.
AIM: 11 beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is considered to contribute to the aetiology of the metabolic syndrome, and specific inhibitors have begun to emerge as treatments for insulin resistance and other facets of the syndrome, including atherosclerosis. Given the role of glucocorticoids and 11beta-HSD1 in the anti-inflammatory response and the involvement of inflammation in the development of atherosclerosis, 11beta-HSD1 inhibition may exacerbate atherosclerosis. Our aim was to investigate in vivo the effects of a specific 11beta-HSD1 inhibitor (2922) on atherosclerosis while assessing glucose homeostasis. METHODS: We conducted a 12-week study administering 2922 (at three doses, 3, 10 and 100 mg/kg body weight) in Ldlr 3KO (Ldlr(-/-)Apob(100/100)Lep(ob/ob)) mice, a genetic model of obesity, insulin resistance, dyslipidaemia and atherosclerosis. Rosiglitazone and simvastatin were used to test the responsiveness of our model in both types of therapy. RESULTS: 2922 was effective in reducing 11beta-HSD1 activity in inguinal adipose tissue (>90% for 100 mg/kg) and was efficacious in improving glucose homeostasis at doses > or =10 mg/kg. Plasma insulin, blood glucose, glucose tolerance and homeostatic model assessment indices were all improved in mice treated with 2922 (100 mg/kg) compared with control animals. Despite an improvement in these parameters, no differences were observed in body weight, adipose or lean tissue masses in the 2922-treated mice. Interestingly, circulating lipids, proinflammatory cytokines and atherosclerosis were unaltered in response to 2922, although a small reduction in LDL cholesterol was detected. CONCLUSIONS: Importantly, 11beta-HSD1 inhibition leads to improved glucose metabolism and does not result in a worsening of atherosclerotic lesion area, yet retained antidiabetic potential in the face of multiple severe metabolic aberrations. This study reinforces the potential use of 11beta-HSD1 inhibitors in patients with the metabolic syndrome without negatively impacting atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Lloyd et al. (2009) studied Combined diabetes, obesity, insulin resistance, dyslipidaemia, and atherosclerosis (mouse model). 11beta-HSD1 inhibitor (2922) vs. Control animals (with rosiglitazone and simvastatin as positive controls) was evaluated on Atherosclerosis and glucose homeostasis (including inguinal adipose 11beta-HSD1 activity). The 11beta-HSD1 inhibitor 2922 reduced adipose 11beta-HSD1 activity (>90% at 100 mg/kg) and improved glucose homeostasis (≥10 mg/kg) without altering atherosclerosis in Ldlr 3KO mice.
Synapse has enriched 10 related papers. Consider them for comparative context: